Latest filings (excl ownership)
10-Q
2024 Q1
Quarterly report
7 May 24
8-K
Beam Therapeutics Reports Pipeline Updates and First Quarter 2024 Financial Results
7 May 24
ARS
2023 FY
Annual report to shareholders
19 Apr 24
DEFA14A
Additional proxy soliciting materials
19 Apr 24
DEF 14A
Definitive proxy
19 Apr 24
S-3ASR
Automatic shelf registration
27 Feb 24
S-8
Registration of securities for employees
27 Feb 24
10-K
2023 FY
Annual report
27 Feb 24
8-K
Beam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Reiterates Anticipated Milestones
27 Feb 24
8-K
Results of Operations and Financial Condition
8 Jan 24
8-K
Beam Therapeutics Appoints Biotech Executive Christi Shaw to its Board of Directors
14 Dec 23
10-Q
2023 Q3
Quarterly report
8 Nov 23
8-K
Beam Therapeutics Reports Pipeline and Business Updates and Third Quarter 2023 Financial Results
8 Nov 23
8-K
Beam Announces Agreement for Lilly to Acquire Beam’s Opt-In Rights to Verve Therapeutics’ Base Editing Programs for Cardiovascular Disease
31 Oct 23
8-K
Cost Associated with Exit or Disposal Activities
19 Oct 23
UPLOAD
Letter from SEC
12 Oct 23
CORRESP
Correspondence with SEC
20 Sep 23
UPLOAD
Letter from SEC
22 Aug 23
CORRESP
Correspondence with SEC
9 Aug 23
10-Q
2023 Q2
Quarterly report
8 Aug 23
8-K
Beam Therapeutics Reports Pipeline Updates and Second Quarter 2023 Financial Results
8 Aug 23
UPLOAD
Letter from SEC
20 Jul 23
8-K
Submission of Matters to a Vote of Security Holders
8 Jun 23
424B5
Prospectus supplement for primary offering
10 May 23
8-K
Entry into a Material Definitive Agreement
10 May 23
10-Q
2023 Q1
Quarterly report
10 May 23
8-K
Beam Therapeutics Reports Pipeline Updates and First Quarter 2023 Financial Results
10 May 23
ARS
2022 FY
Annual report to shareholders
21 Apr 23
DEFA14A
Additional proxy soliciting materials
21 Apr 23
DEF 14A
Definitive proxy
21 Apr 23
S-8
Registration of securities for employees
28 Feb 23
10-K
2022 FY
Annual report
28 Feb 23
8-K
Beam Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Reiterates Anticipated Milestones
28 Feb 23
8-K
Results of Operations and Financial Condition
9 Jan 23
10-Q
2022 Q3
Quarterly report
7 Nov 22
8-K
Beam Therapeutics Announces Portfolio Progress and Reports Third Quarter 2022 Financial Results
7 Nov 22
8-K
Other Events
7 Sep 22
8-K
Other Events
30 Aug 22
10-Q
2022 Q2
Quarterly report
9 Aug 22
8-K
Beam Therapeutics Announces Pipeline and Business Highlights and Reports Second Quarter 2022 Financial Results
9 Aug 22
Latest ownership filings
4
Terry-Ann Burrell
29 Apr 24
144
Notice of proposed sale of securities
4 Apr 24
144
Notice of proposed sale of securities
4 Apr 24
144
Notice of proposed sale of securities
4 Apr 24
144
Notice of proposed sale of securities
4 Apr 24
144
Notice of proposed sale of securities
4 Apr 24
4
Amy Simon
3 Apr 24
4
Christine Bellon
3 Apr 24
4
Terry-Ann Burrell
3 Apr 24
4
John M. Evans
3 Apr 24
4
Giuseppe Ciaramella
3 Apr 24
144
Notice of proposed sale of securities
2 Apr 24
4
Terry-Ann Burrell
2 Apr 24
4
Amy Simon
2 Apr 24
4
Giuseppe Ciaramella
2 Apr 24
4
Christine Bellon
2 Apr 24
4
John M. Evans
1 Apr 24
144
Notice of proposed sale of securities
28 Mar 24
4
Change in insider ownership
15 Feb 24
SC 13G/A
ARCH Venture Fund IX, L.P.
14 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
SC 13G/A
Farallon Capital Partners, L.P.
12 Feb 24
SC 13G/A
FMR LLC
9 Feb 24
SC 13G/A
Temasek Holdings (Private) Ltd
6 Feb 24
4
Terry-Ann Burrell
2 Feb 24
4
Christine Bellon
2 Feb 24
4
Amy Simon
2 Feb 24
4
John M. Evans
2 Feb 24
4
Giuseppe Ciaramella
2 Feb 24
144
Notice of proposed sale of securities
31 Jan 24
SC 13G/A
ARK Investment Management LLC
29 Jan 24
SC 13G/A
BlackRock Inc.
25 Jan 24
SC 13G
STATE STREET CORP
24 Jan 24
4
Christine Bellon
5 Jan 24
4
Change in insider ownership
27 Dec 23
4
Christi Shaw
14 Dec 23
3
Christi Shaw
14 Dec 23
4
Christine Bellon
22 Nov 23
144
Notice of proposed sale of securities
20 Nov 23
4
Amy Simon
1 Nov 23